Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27, 2017
April 24 2017 - 4:00PM
Business Wire
Ignyta, Inc. (Nasdaq:RXDX), a biotechnology
company focused on precision medicine in oncology, today announced
that Ignyta management will host a conference call and live webcast
on April 27, 2017, at 1:30 PM Pacific time (4:30 PM Eastern time)
to provide a comprehensive program update on entrectinib - an
orally available, CNS-active tyrosine kinase inhibitor targeting
tumors that harbor TRK, ROS1 or ALK fusions - currently being
studied in a registration-enabling Phase 2 clinical trial known as
STARTRK-2.
To participate in the conference call, please dial (877)
548-7906 (U.S.) or (719) 325-4765 (International) and provide
Conference ID 2028635. To access the live webcast, go to
https://www.ignyta.com/investors/.
A replay of the presentation will be available shortly after the
conclusion of the live call in the Investors section of the
company's website at https://www.ignyta.com/investors/, and will be
archived and available at that site for 14 days.
About Ignyta, Inc.
Blazing a New Future for Patients with
Cancer™
At Ignyta, we work tirelessly on behalf of patients with cancer
to offer potentially life-saving, precisely targeted therapeutics
(Rx) guided by companion diagnostic (Dx) tests. Our integrated
Rx/Dx strategy allows us to enter uncharted territory, illuminating
the molecular drivers of cancer and quickly advancing treatments to
address them. This approach embraces even those patients with the
rarest cancers, who have the highest unmet need and who may
otherwise not have access to effective treatment options. With our
pipeline of potentially first-in-class or best-in-class precision
medicines, we are pursuing the ultimate goal of not just shrinking
tumors, but eradicating cancer relapse and recurrence in precisely
defined patient populations.
For more information, please visit: www.ignyta.com.
Forward-Looking Statements
This press release contains forward-looking statements about
Ignyta as that term is defined in Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Statements in this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, references to the development of
entrectinib and Ignyta's other product candidates, the potential
advantages and first-in-class or best-in-class nature of these drug
programs and the potential for Ignyta to establish a leadership
position in oncology precision medicine and provide benefit to
cancer patients. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the inherent uncertainties
associated with developing new products or technologies and
operating as a development stage company; Ignyta's ability to
develop, initiate or complete preclinical studies and clinical
trials for, obtain approvals for and commercialize any of its
product candidates; changes in Ignyta's plans to develop and
commercialize its product candidates; the potential for final
results of the ongoing clinical trials of entrectinib or other
product candidates, or any future clinical trials of entrectinib or
other product candidates, to differ from preliminary or expected
results; Ignyta's ability to raise any additional funding it will
need to continue to pursue its business and product development
plans; regulatory developments in the United States and foreign
countries; Ignyta's ability to obtain and maintain intellectual
property protection for its product candidates; the risk that
orphan drug exclusivity may not effectively protect a product from
competition and that such exclusivity may not be maintained; the
potential for the company to fail to maintain the CAP accreditation
and CLIA certification of its diagnostic laboratory; the loss of
key scientific or management personnel; competition in the industry
in which Ignyta operates; and market conditions. These
forward-looking statements are made as of the date of this press
release, and Ignyta assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Investors should consult all of the information set
forth herein and should also refer to the risk factor disclosure
set forth in the reports and other documents the company files with
the SEC available at www.sec.gov, including without limitation
Ignyta's Annual Report on Form 10-K for the year ended December 31,
2016 and subsequent Quarterly Reports on Form 10-Q.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170424005435/en/
Ignyta, Inc.Jacob Chacko, M.D., 858-255-5959CFOjc@ignyta.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Sep 2023 to Sep 2024